Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2022-02-25

FDA Approved: CYSTARAN — Supplemental Application (Leadiant Biosciences, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Cystaran (cysteamine hydrochloride) from Leadiant Biosciences, Inc. The action involves changes to the product label…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cystaran (cysteamine hydrochloride)

Snippet

SUPPL AP for CYSTARAN (CYSTEAMINE HYDROCHLORIDE)